Register to attend a free NCI webinar. Attendees will learn about a new adjuvanted subunit mucosal Covid-19 vaccine. Study results show that this new vaccine prevents SARS-CoV-2 transmission and infection. Most SARS-CoV-2 vaccines focus on delivering immunization through an intramuscular injection. This new technology combines an initial intramuscular injection with subsequent intranasal boost administration of a novel, molecular adjuvant nanoparticle formulation.

The Presenter Jay Berzofsky, M.D., Ph.D. Chief, Vaccine Branch Center for Cancer Research National Cancer Institute

Competitive Advantages

• Stimulates both systemic and mucosal immunity; induces both humoral and cellular immunity, as well as trained innate immunity.
• Leads to more effective virus clearance from the upper respiratory tract from which it could spread.
• Stimulates sustained immune response.
• Protects against SARS-CoV-2 variants.
• Prevents or reduces onward transmission to others, addressing an important public health need.
• Avoids painful injection with intranasal administration .
• Notable improvement for manufacturing yield and cost, ease of administration, and distribution as compared to current candidates.

Commercial Applications:

• Adjuvanted mucosal subunit vaccines (as single agents)
• Vaccine composition(s)
• Co-administration to enhance the effect of systemic immunization.

xIf you cannot attend, you can view further information and licensing contact information on the Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection abstract.